Research Projects Page

The purpose of this article is to describe medication alternatives available for use in patients with certain bleeding disorders during the intranasal desmopressin recall. Intranasal desmopressin plays a key role in treatment of these patients and the recall is expected to impact availability until mid to late 2023. We hope the details of the article can help other institutions select the best treatment alternative for their patients during this time.

This study evaluated adherence rates and health outcomes across three academic centers with integrated specialty pharmacies. Centers with specialty pharmaies had high medicaiton possession ratio (MPR). Self-injectable biologic therapy non-adherence was associated with higher likelihood of emergency department visits and hospitalizations.

This study evaluated patient-reported outcomes (PROs) and pharmacist interventions in patients serviced by VSP in various clinical conditions. In patients with MS specifically, we found that 98% of patients reported no adverse effects, 90% reported no missed doses, and 98% reported their medication worked "good" or "excellent." Pharmacist interventions were commonly related to adherence, safety monitoring, and adverse effects. PROs can be useful to drive meaningful pharmacist interventions.

This study evaluated patient-reported outcomes in neurology specialty disease states gathered via a monthly refill questionnaire. and corresponding pharmacist interventions. There was a high patient-reported adherence rate at 91%. Most pharmacist interventions focused on ensuring safe and effective medication use. Addressing recent healthcare utilization was the most common intervention.

This study evaluates rates and reasons for switching and cycling in patients with RA. The most common reasons for switching and cycling were loss of efficacy, no efficacy and intolerable adverse effects.

This poster evaluates patient characteristics and 3-month outcomes in patients prescribed alternate-dose biologic therapy. Of 220 patients, one-third were previous/current smokers, and 40% had a psychiatric comorbidity. Median disease duration was 11 years (IQR 6-18), 46% previously underwent surgery.

The obejctive of the poster is to describe PrEP medication adhernece and persistence in patients seens at a multidisciplinary PrEP clinic. Patients receiving PrEP in a multidisciplinary clinic with an integrated clinical pharmacist had high rates of adherence and persistene. Patients reported few side effects and reasons for discontinuation were appropriate.

This study assessed DMARD switching, cycling, adherence, and persistence at an outpatient rheumatology clinic with an integrated health-system specialty pharmacy.

Because of the growing focus on outcomes research within Vanderbilt Specialty Pharmacy (VSP) and the need for more student research opportunities, VSP developed a longitudinal student research training program. This report describes the development and outcomes of that program as of June 2021.

This report describes VSP's development of an ASHP-accredited community based residency program in the health-system specialty pharmacy setting.